U.S. Luxury Stock News

Frontdoor (FTDR) delivered robust earnings growth of 24.8% over the past year, comfortably ahead of its five-year average of 21.2% annually. Net profit margins expanded to 13.1% from 11.4% last year, and the company maintained consistently high-quality earnings throughout this period. Looking forward, Frontdoor’s modest growth outlook and classification as good value, against a slightly discounted share price, position operational strength and improved margins at the forefront for investors...

PPL (PPL) reported robust earnings growth, with EPS surging 17.5% for the year and a five-year annualized earnings growth rate of 20.9%. Net profit margin also advanced, reaching 11.2% compared to 10.2% in the prior year. Looking forward, consensus forecasts point to annual earnings growth of 12% and revenue growth around 5%. Both are trailing the broader US market. Investors must also weigh the elevated P/E ratio of 27.3x, with the stock trading well above its estimated fair value. Alongside...

Cricut (CRCT) reported net profit margins of 10.1%, up from 9.2% last year, while delivering 5.7% earnings growth versus its challenging five-year average of -26.8% per year. Long-term, earnings have declined at an average rate of 26.8% annually, and looking forward, revenue is projected to contract by 0.2% annually over the next three years. Investors are weighing improved current profitability and margin expansion against ongoing revenue and earnings headwinds, leaving the market at a...

Thinking about RealReal? If you are wondering whether the recent buzz means it is finally a good value play, you are in exactly the right place. The stock has put up an eye-popping 204.5% gain over the past year, despite some volatile swings, including a recent 6.6% dip in the last week and a 12.7% surge over the past month. Big news has kept RealReal in the spotlight lately, especially as the company continues to expand its e-commerce luxury platform and rethinks operational strategies to...

Mercury General (MCY) reported earnings growth of 22.2% over the last year, with its net profit margin rising to 6.8% from 6.4% a year ago. Earnings have averaged 2% growth per year over the past five years, and the stock’s Price-To-Earnings ratio of 11.6x sits below both peer and industry averages. However, the share price currently trades above modeled fair value. Revenue is expected to grow at 6% annually, which lags the broader US market's 10.5% forecast. The story is one of improving...

Lineage (LINE) remains unprofitable, with net losses deepening at an annual rate of 47.2% over the past five years. While revenue is expected to rise by 6.2% annually, which is below the broader US market’s projected 10.5%, the company is forecast to flip to profitability within three years and drive earnings growth at a robust 58.03% per year. Its current price-to-sales multiple of 1.6x trades well below industry averages and an estimated fair value of $63.34. This places a spotlight on the...

Veracyte (VCYT) has turned the corner on profitability, reporting positive earnings and a stronger net profit margin, marking an important milestone for the company. Over the last five years, earnings have grown at a rapid 29.3% per year, with analysts now forecasting another 26.6% annual earnings growth moving forward. This is well ahead of the broader US market’s outlook for profit growth. While revenue growth is expected to come in at 10.1% per year, just shy of the US average of 10.5%,...

MRC Global (MRC) has delivered a notable turnaround, with earnings climbing at an annual rate of 76% over the past five years and forecasts pointing to ongoing 20% per year growth, well above the broader US market’s 16% outlook. Despite the positive trajectory, revenue growth is expected to trail at 3.9% per year compared to a 10.5% pace for the US market, and net profit margins recently slipped from 2.7% to 1.1%. The stock’s price-to-earnings ratio sits at 36.6x, considerably above peers and...

Western Midstream Partners (WES) reported net profit margins of 33.9%, a step down from last year’s 43.2%, with earnings forecast to grow at 8.7% per year and revenue at 7.6% per year. Both metrics lag behind the broader US market, which expects 16% earnings growth and 10.5% revenue growth annually. Valuation stands out: shares trade at $38.25, well below a DCF-based fair value estimate of $109.22, and the 11.7x price-to-earnings ratio looks attractive compared to the industry average. Amid...

Hippo Holdings (HIPO) remains unprofitable, but the company has managed to reduce its losses by 23% per year over the past five years. Looking ahead, analysts forecast revenue to grow at 15.9% per year, which exceeds the broader US market growth rate of 10.5%. They also project a potential path to profitability within three years. Although profit is not in sight just yet, investors may be watching closely as revenue growth expectations drive sentiment, even as earnings and revenue are not...

Geron (GERN) is set to outpace the broader US market with analysts forecasting revenue growth of 39.2% per year compared to the market’s 10.5% annual rate. While the company remains unprofitable and losses have grown by 14.5% per year over the last five years, Geron is expected to reach profitability within the next three years, a timeline considered above the market average. See our full analysis for Geron. Now, let's see how these headline numbers hold up when compared to the prevailing...

ODP (ODP) reported a net profit margin of 0.7%, down from 2% a year ago, as a one-off loss of $107.0 million weighed on performance over the last twelve months. While the company has averaged 12.3% annual earnings growth since turning profitable, upcoming years are expected to bring a 2.5% annual revenue decline. Investors now face a mixed picture, with ongoing margin pressure and the recent one-off loss on one side, but relative value compared to peers providing a potential bright spot. See...

Flowco Holdings (FLOC) posted a net profit margin of 7.2%, a significant drop from last year’s 23.9%, and also reported negative earnings growth over the past year. Despite the margin squeeze, the company’s earnings quality remains high, and forward guidance calls for 24.2% annual earnings growth, outpacing the US market’s projected 16% per year. With shares currently trading at $18.58, well below the estimated fair value and peer valuations, the market may be weighing near-term margin...

MGE Energy (MGEE) delivered a 13.4% jump in earnings over the last year, far outpacing its 5-year average growth rate of 5.9%. Net profit margin rose to 18.7% from 17.9% a year earlier, underscoring continued profitability. With earnings quality remaining high and growth steady, investors are weighing consistent performance and improved margins against a premium valuation and forecasts that trail the broader market. See our full analysis for MGE Energy. The next section examines how these...

PTC Therapeutics (PTCT) has recently turned profitable, with notable improvements in its net profit margin over the past year. Over the last five years, the company grew its earnings at an annualized rate of 20.9%. However, forecasts are now signaling a reversal, with earnings expected to fall by 46% per year and revenue anticipated to decrease by 2.3% per year over the next three years. Investors are now weighing PTCT’s past margin gains and growth track record against expectations of a more...

Mistras Group (MG) has made a notable leap to profitability, growing earnings at an impressive 71.1% per year over the past five years and only turning profitable in the most recent period. While the company’s reported earnings for the latest 12 months were affected by a one-off $8.6 million loss, the longer-term growth rate remains robust even as short-term results appear volatile. See our full analysis for Mistras Group. Now, let’s see how the fresh earnings numbers measure up to the...

Douglas Emmett (DEI) turned a profit in the most recent year, aided by a substantial one-off gain of $47.2 million that helped lift its net profit margin. Yet, beneath this headline result, the company’s earnings have trended down sharply. Earnings declined 42.8% annually over the past five years and are forecast to fall by a further 87.4% per year over the next three years, with revenue only expected to grow at 2.5% per year. Investors may see value potential as shares change hands at...

DNOW (DNOW) reported EPS that is forecast to grow by 7.9% per year, trailing the broader US market’s expected 16% annual gain. Revenue is projected to increase by 3.8% annually, well below the US market’s 10.5% forecast, while current net profit margins have slipped to 3.4% from last year’s 9.5%. Investors are weighing DNOW’s rapid five-year earnings growth of 65.3% per year and competitive 19x price-to-earnings ratio against a recent pullback in profitability, with the stock trading at...

Sportradar Group (SRAD) posted robust results with net profit margins jumping to 9.2% from 2.7% in the prior year, while annual earnings growth hit a dramatic 313.4%, easily outstripping the company’s already strong five-year average of 40.4% per year. Revenue is projected to grow at 13.2% per year, above the broader US market’s 10.5% expectation, and earnings are expected to climb 27.2% annually, leaving much of the competition trailing. This performance, paired with a current share price of...

TXO Partners (TXO) has turned a corner into profitability over the past year, delivering a net profit margin where there previously was none. Earnings are forecast to grow at 9.3% per year, while revenue is expected to increase at 8.4% per year. Both rates sit below broader US market averages. For investors, the shift to profits, sustainable dividend, and strong earnings quality now set the backdrop for a company trading below intrinsic value but carrying a higher-than-average P/E...

Avanos Medical (AVNS) remains unprofitable, with losses widening at an average rate of 74.4% per year over the past five years. Improving profit growth has proven elusive and the company’s net profit margin shows no sign of a turnaround. Despite these challenges, investors may still see a potential value play as persistent profitability headwinds are set against a discounted valuation and a share price of $10.66, which is notably below the estimated fair value of $45.32. See our full analysis...

AudioEye (AEYE) remains unprofitable but has steadily narrowed its losses over the last five years at an annual rate of 18.4%. Revenue is now forecast to grow 11.5% per year, topping the US market average of 10.5%, even as net profit margins are yet to turn positive. Investors weighing the numbers will note that the company is valued at a 4.7x Price-to-Sales ratio and currently trades at $14.43, below the estimated fair value of $16.72. This keeps the spotlight on its growth prospects and...

Amicus Therapeutics (FOLD) is still unprofitable, but recent statements point to a projected earnings growth rate of 50.98% per year and forecasts for the company to reach profitability within the next three years. Revenue growth is expected at 16.6% annually, outpacing the US market’s 10.5% rate. Losses have been reduced at a rate of 28% per year over the past five years. The current setup offers investors a constructive outlook with strong signals around profit and revenue growth, and no...

Hut 8 (NasdaqGS:HUT) is expected to grow revenue by an impressive 49.97% per year, far outpacing the broader US market’s 10.5% annual forecast. However, net profit margins are down from last year and earnings are forecast to decline steeply at 72.5% per year over the next three years, with the latest annual earnings growth slowing to just 2% compared to a five-year average of 61.9%. Investors are weighing strong revenue growth projections and a Price-to-Earnings ratio of 25x, which is lower...